Forward Outlook and Clinical Insights in Melanoma Treatment


A group of oncology experts provide forward-looking perspectives and clinical insights in the treatment of melanoma.

This is a video synopsis/summary of an OncLive Insights involving Afreen Shariff, MD, MBBS; Javid Moslehi, MD; and Nikhil Khushalani, MD.

In conclusion, Dr Khushalani notes much progress in improving melanoma survivorship but cautions emerging immunotherapies will likely bring more toxicities requiring adept management. He foresees greater predictive modeling and molecular testing enabling personalized toxicity risk assessments to guide informed treatment decisions. Dr Shariff expects cancer will follow other chronic diseases with greatly improved long-term outcomes thanks to advancing therapies, necessitating increased focus on survivorship care quality. Dr Moslehi closes by celebrating progress in metastatic melanoma thanks to oncology innovations, requiring a collaborative multidisciplinary approach across specialties to provide comprehensive patient care going forward.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.

Related Videos
Video 4 - "Challenges in Adopting Targeted Therapies for BRAF Alterations"
Video 3 - "BRAF V600E Mutant Ganglioglioma"
Video 10 - "SELECT Trial & DECISION Trial Outcomes and Lessons Learned"
Video 9 - "Identifying RAI-Refractory Disease: A Key Aspect of DTC Management"
Video 18 - "Future Perspectives and Unmet Needs in Renal Cell Carcinoma"
Video 17 - "Nivolumab Plus Cabozantinib in Non–Clear Cell RCC"
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Video 16 - "Trajectory of Evolving HCC Treatment Landscape"
Related Content